The present invention relates to a topical composition that can be applied to a subject's outer skin such as abdominal area, neck area, chest area, arms, legs, or buttocks to treat skin laxity, cellulite and to firm, smooth and/or tone skin. The topical composition contains a tripeptide, a tetrapeptide and one or more botanical extracts.
A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
Glaucoma can be treated by implanting an intraocular shunt in the eye. The implantation can be performed by first determining an entry area below a corneal limbus of an eye. Thereafter, the intraocular shunt can be inserted into eye tissue through the entry area such that an inflow end of the shunt is positioned in the anterior chamber of the eye and an outflow end of the shunt is positioned between layers of Tenon's capsule.
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Providing networking services for healthcare professionals in the field of neuroscience, including psychiatry, Parkinson's Disease and migraine treatment. Education services, namely, providing classes, workshops, and in-person discussion forums in the field of neuroscience, including psychiatry, Parkinson's Disease and migraine treatment. Providing medical information in the field of neuroscience, including psychiatry, Parkinson's Disease and migraine treatment.
6.
NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR
The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering nanoparticle compositions (e.g., nanoparticle compositions comprising at least one known therapeutic agent and/or independently active biologically active agent; and/or empty nanoparticle compositions) to a subject in need thereof.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
B29C 65/48 - Joining of preformed partsApparatus therefor using adhesives
B29K 83/00 - Use of polymers having silicon, with or without sulfur, nitrogen, oxygen or carbon only, in the main chain, as moulding material
Operation of telephone call centers for healthcare professionals in the field of eye care products; customer services, namely, responding to customers inquiries for health care professionals in the field of eye care products via telephone or other electronic means
Stabilized ophthalmic compositions containing omega-3 oils are provided, which are useful as artificial tears and as ophthalmic compositions to diagnose, treat, or prevent keratoconjunctivitis or dry eye syndrome in a human or other mammal.
The present invention relates to method of lowering intraocular pressure in a subject in need of such treatment, which comprises administering a therapeutically effective amount of a composition comprising [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, or enantiomers thereof, or tautomers thereof, pharmaceutical compositions containing them and their use as pharmaceuticals
Devices and methods for inserting an implant into skin or other tissue of a patient can include a hyaluronic thread that is coupled at a distal portion with an insertion device. The insertion device can include a cover member and a piston that can collectively facilitate engagement with or disengagement of the distal portion of the thread with the device. For example, the piston can be positioned within an inner cavity of the cover member, and the distal portion of the thread can be engaged by and/or between the piston and the cover member. The thread can be released by movement of the piston relative to the cover member. Thus, some insertion devices can grasp or engage the distal portion of the thread and “push” the distal portion of the thread into and through into skin or other tissue of a patient.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
Glaucoma can be treated by implanting an intraocular shunt into the eye. Such procedures can employ various deployment devices, shunts, and implantation techniques. A method of treating glaucoma can be performed by a clinician, in which a hollow needle is inserted into an eye through the sclera. The hollow needle can carry an intraocular shunt. Once inserted and properly positioned, the clinician can release the shunt from the needle such that the shunt conducts fluid away from the anterior chamber of the eye.
A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/335 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/43 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
A method of manufacturing an accommodating intraocular lens including molding an optical component having at least a central portion formed of an optically clear silicone material; molding a second component, the second component comprising a silicone material; activating surfaces of the optical component and surfaces of the second component in a plasma chamber; and covalently bonding together without adhesive the optical component and the second component to form a lens capsule having an internal chamber.
Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A breast implant is provided which includes a filling, or core having a lower overall density relative to silicone gel-filled or saline-filled implant. The core may be a composite including flexible, bodies, for example, air-containing, or gas-containing, bodies, and a gel medium between or around the bodies.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Surgical mesh comprised primarily of living tissue; biological tissue grafts; biological porcine acellular dermal tissue intended for subsequent implantation
(2) Surgical mesh comprised primarily of artificial materials; surgical implants and mesh made of synthetic materials for use in soft tissue repair or the reconstruction of soft tissue deficiencies; medical devices and apparatus, namely, surgical implants comprised primarily of artificial material and also incorporating processed animal tissue for use in plastic reconstructive surgery, and repair, reinforcement or buttressing of soft tissue, and parts and fittings therefor
Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Provided herein are methods for improving the appearance of platysma prominence associated with platysma muscle activity to a human patient, by administering a composition comprising a botulinum toxin type A to the human patient's platysma muscle. Preferably, the methods involve injection of the composition into the upper segment of the platysma muscle, below the jawline of the human patient and injection of the composition along one or more continuous neck bands on the neck of the human patient.
Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
Provided herein are methods for improving the appearance of platysma prominence associated with platysma muscle activity to a human patient, by administering a composition comprising a botulinum toxin type A to the human patient's platysma muscle. Preferably, the methods involve injection of the composition into the upper segment of the platysma muscle, below the jawline of the human patient and injection of the composition along one or more continuous neck bands on the neck of the human patient.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Cosmetic ingredient complex composed of fructooligosaccharides, polyphenols, and glycoproteins sold as an integral component of non-medicated skincare preparations; Cosmetic ingredient complex composed of antioxidants and humectants sold as an integral component of non-medicated skincare preparations; Cosmetic preparations; Cosmetics; Non-medicated skin care preparations; Sun screen preparations; Cosmetic preparations for skin care
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Cosmetic ingredient complex composed of fructooligosaccharides, polyphenols, and glycoproteins sold as an integral component of non-medicated skincare preparations; Cosmetic ingredient complex composed of antioxidants and humectants sold as an integral component of non-medicated skincare preparations; Cosmetic preparations; Cosmetics; Non-medicated skin care preparations; Sun screen preparations; Cosmetic preparations for skin care
27.
FLOWABLE ACELLULAR TISSUE MATRIX PRODUCTS AND METHODS OF PRODUCTION
Tissue product compositions and methods for treating a patient are provided. The tissue product composition may include a flowable carrier including a hyaluronic acid based material and acellular tissue matrix particles mixed within the carrier. Methods of producing the tissue product composition and an injection device filled with the tissue product composition are also provided.
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical information services, namely, providing health information relating to dermal filler, skin rejuvenation, scar remodeling and tissue repair technology
29.
METHOD FOR IMPROVING DURATION OF EFFECT OF DERMAL FILLER TREATMENT
A method of treating midface volume deficit in a person is provided. The method generally includes administering a dermal filler, such as a hyaluronic acid based dermal filler, in a sequence of injections that enhance effectiveness and/or duration of the filler. The method may include initially introducing a volume of the filler into at a zygomaticomalar region of the face prior to introducing one or more additional volumes of the filler into the anteromedial region and the submalar region, such that the duration of effectiveness of the treatment is improved, and less filler is required to achieve a desired correction.
Operation of telephone call centers for healthcare professionals in the field of eye care products; customer services, namely, responding to customers inquiries for health care professionals in the field of eye care products via telephone or other electronic means
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
providing consumer product information relating to facial and medical aesthetics products to healthcare professionals and medical aesthetics practitioners via the internet; providing a website featuring information about medical and medical aesthetics practice management and administrative support services to healthcare professionals and medical aesthetics practitioners; providing online information for healthcare professionals and medical aesthetics practitioners about medical and medical aesthetics practice management and administrative support related to facial and medical aesthetics products, and inventory management for facial and medical aesthetics products; administration of a customer loyalty program which provides incentives, rebates and rewards for frequent purchases of facial and medical aesthetics products; administration of a program for enabling participants to obtain discounts on facial and medical aesthetics products pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; biological dermal implants, namely, visco-supplementation solutions for filling wrinkles apparatus for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin educational services, namely, conducting classes, workshops and training seminars in the fields of facial and medical aesthetics; providing online non-downloadable digital educational publications in the nature of newsletters, blogs, articles, magazines and journals, all in the fields of facial and medical aesthetics; providing educational resources, namely, conducting classes and workshops and training services to licensed healthcare professionals and medical aesthetics practitioners in the fields of facial and medical aesthetics medical information services, namely, providing medical information concerning the use of facial and medical aesthetics products and about facial and medical aesthetics treatments to healthcare professionals and medical aesthetics practitioners via the internet
32.
BREAST PROSTHESES, METHODS OF MANUFACTURING BREAST PROSTHESES, AND METHODS OF TREATMENT USING BREAST PROSTHESES
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
B29C 65/48 - Joining of preformed partsApparatus therefor using adhesives
B29K 83/00 - Use of polymers having silicon, with or without sulfur, nitrogen, oxygen or carbon only, in the main chain, as moulding material
The present application relates to use of transglutaminases to treat various tissue matrix products. The methods can include application of a transglutaminase to a partially denatured collagen-containing tissue matrix and implantation of the tissue matrix. The transglutaminase can facilitate adhesion with another collagen-containing tissue matrix, tissue surrounding the tissue matrix after implantation, or both.
A01N 1/126 - Physiologically active agents, e.g. antioxidants or nutrients
A01N 1/128 - Chemically defined matrices for immobilising, holding or storing living parts, e.g. alginate gelsChemically altering living parts, e.g. by cross-linking
Topical formulations for restoring healthy skin are provided, by for example, restoring the skin barrier by maintaining a beneficially balanced microbiome. Skin care cleansing and/or moisturizing formulations are provided in some embodiments in which select ingredients work together to hydrate the skin, bring balance to or otherwise improve the skin microbiome, and improve the barrier function of the skin.
A61K 8/18 - Cosmetics or similar toiletry preparations characterised by the composition
A61K 8/96 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution
Described are implantable devices having reservoirs for the sustained release of therapeutic agents. The devices are configured to be at least partially implanted in an eye and include a retention structure and a penetrable element coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element is positioned in fluid communication with an outlet of the device and a reservoir having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 9/00 - Medicinal preparations characterised by special physical form
A layered microneedle device with successively stacked layers wherein each layer includes microneedles and perforations positions between the microneedles. The layers can be stacked to permit microneedles of a lower layer to extend through the perforations of an upper layer. The microneedles of successively stacked layers can extend away from the individual layers in a common direction.
Described herein are assisted syringes. The syringes provide a higher force to the plunger tip than the extrusion force applied to the plunger. The assisted syringes can be used to inject or extrude viscous materials.
A prosthesis can include a shell and a needle guard coupled to a posterior portion of the shell. The shell can include a laminate having a base layer, a top layer, and a soft silicone gel intermediate layer disposed between the base layer and the top layer and of sufficient thickness for self-sealing of a needle hole therethrough. The needle guard can include a plurality of offset layers of offset, puncture-resistance structures that, in an expanded state, (i) collectively form a concave shape and (ii) provide a concave exterior surface along the posterior portion of the prosthesis for approximating a human anatomical feature. The needle guard can have a shape memory characteristic for urging the prosthesis toward the expanded state.
Devices and methods of regulating intraocular pressure can include implanting an intraocular shunt into an eye at a desired location within the sclera. Some methods involve creating an opening in the sclera, and positioning a shunt in the anterior chamber of the eye such that the shunt terminates via the opening in the intrascleral space, thereby facilitating fluid flow through both the opening and the intrascleral space.
A61F 2/14 - Eye parts, e.g. lenses or corneal implantsArtificial eyes
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61F 9/008 - Methods or devices for eye surgery using laser
A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61B 17/00 - Surgical instruments, devices or methods
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
Cosmetic ingredient complex composed of iron oxide pigments sold as an integral component of non-medicated skincare preparations; Cosmetic preparations; Non-medicated skin care preparations
42.
COMPOSITE TISSUE PRODUCT ANCHOR BOLSTER FOR THREE-DIMENSIONAL BIOLOGIC SCAFFOLDS AND RELATED METHODS
The present disclosure provides anchor bolsters for three-dimensional biologic scaffolds, including related methods of formation and use. The composite bolster-scaffold provides an improved device to securely anchor a three-dimensional tissue scaffold in position relative to surrounding anatomic structures, allowing time for colonization of native cells and subsequent incorporation of the three-dimensional tissue scaffold by the recipient tissue bed.
An implanted intraocular shunt can be manually manipulated, without surgical intervention, to modify the flow resistance of the shunt, thereby providing relief from high intraocular pressure while avoiding hypotony. For example, through application of pressure along a surface of the eye, a portion of the shunt can be displaced or separated relative to the shunt, thereby decreasing a flow resistance of the shunt.
Methods and Systems for evaluating visual impairment of a user. The methods and systems including generating, using a processor, a virtual reality environment; displaying at least portions of the reality environment on a head-mounted display, and measuring the performance of a user as user interacts with the virtual reality environment using at least one performance metric. Non-transitory computer readable storage medium comprising a sequence of instructions for a processor to execute the methods discussed herein.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/02 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient
A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing light sensitivity, e.g. adaptationSubjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
A61B 3/09 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing accommodation
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
G02B 27/00 - Optical systems or apparatus not provided for by any of the groups ,
G06T 19/00 - Manipulating 3D models or images for computer graphics
G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
45.
COMPOSITE TISSUE PRODUCT ANCHOR BOLSTER FOR THREE-DIMENSIONAL BIOLOGIC SCAFFOLDS AND RELATED METHODS
The present disclosure provides anchor bolsters for three-dimensional biologic scaffolds, including related methods of formation and use. The composite bolster-scaffold provides an improved device to securely anchor a three-dimensional tissue scaffold in position relative to surrounding anatomic structures, allowing time for colonization of native cells and subsequent incorporation of the three-dimensional tissue scaffold by the recipient tissue bed.
Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a silk fibroin component.
The present invention provides ophthalmic compositions, e.g. artificial tears, suitable for treating dry eye syndrome in a human or other mammal suffering there from, e.g. a dog or cat, which comprise a mixture of castor oil with another oil, e.g. a food oil. e. g. olive oil, sesame oil, corn oil etc.
A61K 36/47 - Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention relates to delayed release pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 5/46 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for controlling depth of insertion
Disclosed herein are flowable tissue matrix compositions comprising small pieces of partially or completely decellularized tissue suspended in a gelatinized tissue or gelatin gel comprising partially or completely decellularized tissue or synthetic gelatin. The flowable tissue matrix compositions can contain factors that promote or enhance native cell migration, proliferation, and/or revascularization after implantation into a subject. Also disclosed are methods of making and using the flowable tissue matrix compositions. The compositions can be implanted into a tissue in need of repair, regeneration, healing, treatment, and/or alteration, and can promote or enhance native cell migration, proliferation, and/or revascularization.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
Compositions and methods for treating tissue are provided. The compositions may include tissue matrix derived from adipose tissue suitable for injection, small-volume implantation, or use as a soft-tissue regenerative material. Also provided are methods for producing such compositions.
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
The present invention is directed to compositions and methods for treating ocular conditions, including presbyopia, mild hyperopia, irregular astigmatism, hyperopic accommodative esotropia, and glaucoma. The compositions can also be used to potentiate or enhance interventions that retard, reverse, or modify the aging process of the crystalline lens and its surrounding tissues. The compositions include a cholinergic agent, such as a muscarinic acetylcholine receptor M3 agonist, and an alpha agonist having an imidazoline group or a non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity. It has been found that an alpha agonist having an imidazoline group or non-steroidal anti-inflammatory agent (NSAID) having COX-2 selectivity in combination with a cholinergic agent, such as pilocarpine, act synergistically to improve the accommodative and focusing ability of the eye while minimizing the side effects from each compound.
A61K 31/4174 - Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
53.
POLYMER SYSTEM FOR SECURING IMPLANTS IN SYRINGE NEEDLES
Disclosed herein are methods of delivering implants to a target organ with an implant administration device, where the implant administration device includes a polymer retainer. Methods of making polymer retainers and methods of securing an implant within an implant administration device using a polymer retainer are also disclosed herein.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
Disclosed is an intraocular lens device for treatment of an eye including a shape changing membrane configured to outwardly bow in a region surrounding the optical axis of the eye. The lens device also includes a force translation arm configured to move upon movement of the ciliary structure.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61F 9/008 - Methods or devices for eye surgery using laser
Surgical mesh comprised primarily of artificial materials; Surgical implants and mesh made of synthetic materials for use in soft tissue repair or the reconstruction of soft tissue deficiencies; Medical devices and apparatus, namely, surgical implants comprised primarily of artificial material and also incorporating processed animal tissue for use in plastic reconstructive surgery, and repair, reinforcement or buttressing of soft tissue, and parts and fittings therefor
Glaucoma can be treated by implanting an intraocular shunt into an eye. The eye has an anterior chamber and sclera. A shunt can be placed into the eye to establish fluid communication from the anterior chamber of the eye through the sclera. Further, a pharmaceutical or biological agent can be administered to the eye.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A fluid injection device can include a plurality of needles, a hub from which the needles project, and a base component. The hub can have a directing portion extending therefrom. The plurality of needles can each be in fluid communication with a respective needle base, and the needle bases can at least partially surround the directing portion. The directing portion can extend in a direction away from the hub for diverting flow toward the plurality of needle bases. The base component can be separate from and coupleable to the hub such that when coupled thereto, the hub directing portion extends into a cavity of the base component upstream of the plurality of needle bases.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61B 17/00 - Surgical instruments, devices or methods
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Described here are devices, systems, and methods for treating one or more conditions (such as dry eye) or improving ocular health by providing stimulation to nasal or sinus tissue. Generally, the devices may be handheld or implantable. In some variations, the handheld devices may have a stimulator body and a stimulator probe having one or more nasal insertion prongs. When the devices and systems are used to treat dry eye, nasal or sinus tissue may be stimulated to increase tear production, reduce the symptoms of dry eye, and/or improve ocular surface health.
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
A61F 7/12 - Devices for heating or cooling internal body cavities
A61H 1/00 - Apparatus for passive exercisingVibrating apparatusChiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
A61H 21/00 - Massage devices for cavities of the body
A61H 23/02 - Percussion or vibration massage, e.g. using supersonic vibrationSuction-vibration massageMassage with moving diaphragms with electric or magnetic drive
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
The present disclosure provides devices and methods for treating the breast. The devices can include an acellular tissue matrix having a predefined shape. The shape can include a first edge with an S-shaped configuration and a second arcuate-shaped edge. The shape alternatively can include a first concave edge and a second convex edge.
A needle assembly for an injection device is provided to facilitate delivery of a dermal filler. The assembly includes a cannula and a hub. The hub can be coupled to a syringe. The hub includes an inner bore that has a proximal retention section, a stepped section, and a cannula retention section. The stepped section, the proximal retention section, and the cannula retention section are configured to reduce the dead space within the inner bore for preventing detachment of the hub from the syringe during an injection procedure.
A61M 5/34 - Constructions for connecting the needle
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
An ab externo method of placing an intraocular implant into an eye can include advancing a needle, in which the implant is disposed, into the eye through sclera of the eye. The implant can include a drug deliverable to the eye. The implant can thereafter be released to be anchored in the eye and elute the drug to the eye.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 9/00 - Medicinal preparations characterised by special physical form
A composite drug delivery material may be injected into an eye of a human being or mammal to provide sustained delivery of the drug. A composite drug delivery material may include a plurality of microparticles dispersed in a media composition. The microparticles may contain a drug and a coating comprising a bioerodible material or a biodegradable material, and the media composition includes the drug dispersed in a depot-forming material. The media composition may gel or solidify upon injection into the eye.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A system for deploying an intraocular shunt can include an intraocular shunt inserter and a deflector component that is releasably attachable to a distal end portion of the inserter. The inserter can include a housing having a distal end portion and a needle extending from the distal end portion. The deflector component can have a needle guide configured to receive the needle of the inserter therein. The deflector component can be coupled to the inserter in order to permit the needle guide to bend the needle and maintain the needle in a bended configuration.
The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular tissue matrices for treatment of a breast or particulate products. The products can include adipose matrix and tropoelastin.
Skin can be treated by piercing skin with a plurality of needles of an injection device and ejecting a dose of fluid therethrough. The device can include a housing, a plunger disposed in the housing, a cartridge disposed in the housing, and one or more dosing chambers. The plurality of needles can be coupled to the housing and be in fluid communication with the cartridge. Advancement of the plunger can cause a dose of fluid to be ejected from the plurality of needles.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Devices with improved biomechanical properties and methods for treating tissue are provided. The compositions may comprise acellular tissue matrices specifically shaped and sized for facial and neck implantation and having variations in mechanical and/or biological properties. Also provided are methods for treating tissue using these devices.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A61L 27/50 - Materials characterised by their function or physical properties
68.
DEVICES, SYSTEMS, AND METHODS FOR TISSUE PROCESSING
The present disclosure provides devices and methods for processing and harvesting adipose tissue. The present disclosure provides improved devices, systems, and methods for harvesting, processing, and filtering adipose tissue for autologous fat transfer procedures. The features of the devices and systems of the present disclosure increase efficiency and sterility of adipose tissue processing by reducing the need for users to interrupt the procedure to adjust some part of the system, such as unclogging filter pores or adjusting tubing.
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
B01D 29/23 - Supported filter elements arranged for outward flow filtration
B01D 29/64 - Regenerating the filter material in the filter by scrapers, brushes or the like, acting on the cake side of the filtering element
B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
Graft materials and devices for surgical breast procedures may include a sheet of biocompatible material and a plurality of fenestrations distributed across a portion of the sheet of biocompatible material. The sheet of biocompatible material can have a first axis and a second axis coincident with the sheet of biocompatible material. The sheet of biocompatible material can also have a first edge that intersects the second axis and a second edge that intersects the second axis. The first axis can be orthogonal to the second axis. The plurality of fenestrations can be distributed across a portion of the sheet of biocompatible material closer to the first edge than the second edge. Other apparatuses and methods are disclosed.
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
The present disclosure relates to tissue matrix products. The products can includes tissue matrices that have holes or perforations located at certain positions to improve certain in vivo functions without substantial loss of strength or other important properties.
A61L 27/50 - Materials characterised by their function or physical properties
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
Compositions that include extracellular matrix material and/or conditioned medium obtained from cells cultured under hypoxic conditions in a suitable growth medium and methods for producing the compositions. The compositions may also include botanicals, peptides, seed extracts, marine extracts and/or bacterial ferments. The compositions may be used to repair and regeneration of skin tissue.
C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
A61K 8/64 - ProteinsPeptidesDerivatives or degradation products thereof
A61K 8/97 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from algae, fungi, lichens or plantsCosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from derivatives thereof
A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular extracellular matrices. In addition, the present disclosure provides systems and methods for using such products.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin biological dermal implants, namely, visco-supplementation solutions for filling wrinkles. Apparatus for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin. Providing consumer product information relating to facial and medical aesthetics products to healthcare professionals and medical aesthetics practitioners via the internet; providing a website featuring information about medical and medical aesthetics practice management and administrative support services to healthcare professionals and medical aesthetics practitioners; providing online information for healthcare professionals and medical aesthetics practitioners about medical and medical aesthetics practice management and administrative support related to facial and medical aesthetics products, and inventory management for facial and medical aesthetics products; administration of a customer loyalty program which provides incentives, rebates and rewards for frequent purchases of facial and medical aesthetics products; administration of a program for enabling participants to obtain discounts on facial and medical aesthetics products. Educational services, namely, conducting classes, workshops and training seminars in the fields of facial and medical aesthetics; providing online non-downloadable digital educational publications in the nature of newsletters, blogs, articles, magazines and journals, all in the fields of facial and medical aesthetics; providing educational resources, namely, conducting classes and workshops and training services to licensed healthcare professionals and medical aesthetics practitioners in the fields of facial and medical aesthetics. Medical information services, namely, providing medical information concerning the use of facial and medical aesthetics products and about facial and medical aesthetics treatments to healthcare professionals and medical aesthetics practitioners via the internet.
74.
3,4-DISUBSTITUTED 3-CYCLOBUTENE-1,2-DIONES AND USE THEREOF
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:
Described herein are compounds, or pharmaceutically acceptable salts thereof, of the following formula:
The compounds are useful for treating inflammatory and autoimmune diseases.
C07C 311/39 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07B 59/00 - Introduction of isotopes of elements into organic compounds
C07C 211/52 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having amino groups bound to only one six-membered aromatic ring the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
C07C 237/44 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
C07C 311/43 - Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
C07D 215/42 - Nitrogen atoms attached in position 4
C07D 307/36 - Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
C07D 307/79 - Benzo [b] furansHydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
C07D 333/54 - Benzo [b] thiophenesHydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, biological dermal implants, namely, visco-supplementation solutions for filling wrinkles
(2) Apparatus for the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin (1) Providing consumer product information relating to facial and medical aesthetics products to healthcare professionals and medical aesthetics practitioners via the internet; providing a website featuring information about medical and medical aesthetics practice management and administrative support services to healthcare professionals and medical aesthetics practitioners; providing online information for healthcare professionals and medical aesthetics practitioners about medical and medical aesthetics practice management and administrative support related to facial and medical aesthetics products, and inventory management for facial and medical aesthetics products; administration of a customer loyalty program which provides incentives, rebates and rewards for frequent purchases of facial and medical aesthetics products; administration of a program for enabling participants to obtain discounts on facial and medical aesthetics products
(2) Educational services, namely, conducting classes, workshops and training seminars in the fields of facial and medical aesthetics; providing online non-downloadable digital educational publications in the nature of newsletters, blogs, articles, magazines and journals, all in the fields of facial and medical aesthetics; providing educational resources, namely, conducting classes and workshops and training services to licensed healthcare professionals and medical aesthetics practitioners in the fields of facial and medical aesthetics
(3) Medical information services, namely, providing medical information concerning the use of facial and medical aesthetics products and about facial and medical aesthetics treatments to healthcare professionals and medical aesthetics practitioners via the internet
The present disclosure provides meshed acellular dermal tissue matrix compositions, devices, and methods of use. The meshed devices can be used in conjunction with a variety of implants such as breast implants or tissue expanders.
A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
A61B 17/06 - NeedlesHolders or packages for needles or suture materials
A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
Disclosed herein are muscle implants and methods of making muscle implants comprising one or more decellularized muscle matrices. The muscle matrices can be provided in a particulate form suitable for injection or implantation.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
pharmaceutical preparations containing hyaluronic acid for the treatment of facial wrinkles, asymmetries, defects and conditions of the human face and neck; pharmaceutical preparations for the treatment of neuromuscular disorders; pharmaceutical preparations containing botulinum toxin for the treatment of facial lines, wrinkles, asymmetries, defects and conditions of the human face and neck Providing cosmetic research information to physicians, medical practitioners and their patients in the field of treatments containing botulinum toxin; providing cosmetic research information to physicians, medical practitioners and their patients relating to treatments of facial wrinkles, asymmetries, defects and conditions of the human face and neck.
Described herein are methods and compositions for the treatment of ocular conditions and for the improvement of vision parameters using pharmaceutically acceptable ophthalmic pilocarpine formulations. A nonlimiting example of an ocular condition that may be treated with the methods and compositions disclosed herein is presbyopia.
Provided herewith is a needle for delivering dermal filler thread to a wrinkle in a patient. The needle can also be used to deliver the thread to a patient for the purposes of facial contouring. The needle comprises a coupler for attaching the thread to the needle and also a trocar to ease delivery through the skin.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61L 17/10 - At least partly resorbable materials containing macromolecular materials
A61L 17/12 - Homopolymers or copolymers of glycolic or lactic acid
82.
CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION
Hydrogels comprising a macromolecular matrix and water may be used to augment soft tissue of a human being, promote or support cell or tissue viability or proliferation, create space in tissue, and for other purposes. A macromolecular matrix may comprise a hyaluronic acid component crosslinked to a collagen component.
Compositions useful as dermal fillers and methods using such compositions to treat various skin and soft tissue conditions. The dermal fillers can comprise silk attached to hyaluronic acid using for example two cross linkers and can be used to treat of facial imperfections, facial defects, facial augmentations, breast imperfections, breast augmentations or breast reconstructions.
Disclosed herein are muscle implants and methods of making muscle implants comprising one or more decellularized muscle matrices. The muscle matrices can, optionally, be joined to one or more decellularized dermal matrices. The muscle implants can be used to enhance muscle volume or to treat muscle damage, defects, and/or disorders. The decellularized muscle matrices in the implants retain at least some of the myofibers found in a muscle tissue prior to processing.
Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Described here are devices, systems, and methods for treating one or more conditions (such as dry eye) or improving ocular health by providing stimulation to nasal or sinus tissue. Generally, the devices may be handheld or implantable. In some variations, the handheld devices may have a stimulator body and a stimulator probe having one or more nasal insertion prongs. When the devices and systems are used to treat dry eye, nasal or sinus tissue may be stimulated to increase tear production, reduce the symptoms of dry eye, and/or improve ocular surface health.
A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
A61F 7/12 - Devices for heating or cooling internal body cavities
A61H 1/00 - Apparatus for passive exercisingVibrating apparatusChiropractic devices, e.g. body impacting devices, external devices for briefly extending or aligning unbroken bones
A61H 21/00 - Massage devices for cavities of the body
A61H 23/02 - Percussion or vibration massage, e.g. using supersonic vibrationSuction-vibration massageMassage with moving diaphragms with electric or magnetic drive
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
A61K 31/559 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing hetero atoms other than oxygen
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61L 27/58 - Materials at least partially resorbable by the body
88.
USE OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR IMPROVING VISION
Methods of using the alpha-2-adrenergic receptor agonist of Formula I:
Methods of using the alpha-2-adrenergic receptor agonist of Formula I:
Methods of using the alpha-2-adrenergic receptor agonist of Formula I:
for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.
An inserter for treating glaucoma can comprise a housing, a needle, a plunger, a slider component, and a drive component. The drive component is disposed within a cavity of the housing and rotatable within the cavity to result in movement along a longitudinal axis of the inserter to the needle and the plunger upon rotation of the drive component. The slider component is coupled to the housing and slidable along an elongate groove of the drive component such that movement of the slider component along the axis rotates the drive component within the housing.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
A61M 27/00 - Drainage appliances for wounds, or the like
A method of manufacturing a tissue expander for implanting into a body of a living subject can include mixing granules of a solute with an elastomer. The method can further include forming a matrix with the elastomer. The granules can be embedded within the elastomer. The elastomer can define boundaries of a plurality of chambers within the matrix. The method can further include curing the elastomer, such that the boundaries of the matrix are permeable to water at a temperature between a desired temperature range.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
A61L 27/48 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with macromolecular fillers
A61L 27/50 - Materials characterised by their function or physical properties
91.
HYALURONIC ACID-COLLAGEN MATRICES FOR DERMAL FILLING AND VOLUMIZING APPLICATIONS
Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.
Disorders such as headaches can be treated by administration of a botulinum toxin to a patient suffering therefrom, such as a migraine headache. A combined a fixed site/fixed dose and an optional follow the pain variable dosage and injection site paradigm is disclosed for optimizing clinical effectiveness of botulinum toxin administration for patients suffering headache, particularly chronic migraine.
A tapered sleeve is provided that includes a hydrophilic coating on an inner surface. In use, the device is typically removed from sterile packaging and soaked to activate the lubricous properties of the coating. An implant (e.g., a pre-filled silicon breast implant) is introduced into a large end of the sleeve and extruded into a surgical pocket of minimal access incision size through a small-sized end of the device.
The present invention provides highly injectable, long-lasting hyaluronic acid-based hydrogel dermal filler compositions made with a di-amine or multiamine crosslinker in the presence of a carbodiimide coupling agent.
Methods of using the alpha-2-adrenergic receptor agonist of Formula I:
Methods of using the alpha-2-adrenergic receptor agonist of Formula I:
Methods of using the alpha-2-adrenergic receptor agonist of Formula I:
for improving vision such as in the treatment of ocular conditions such as presbyopia, poor night vision, visual glare, visual starbursts, visual halos, and some forms of myopia (e.g. night myopia) are described.
